,48 Fianlimab blocks LAG-3 binding to MHC class II, activating T cells and enhancing cytotoxic T-cell-mediated tumor cell lysis (https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fianlimab). The gene discussed is LAG3; the disease is cancer.